Venous Thromboembolism Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Venous Thromboembolism market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Pfizer, Bristol-Myers Squibb, Bayer, Janssen LLC, Johnson & Johnson Pharma, Cristália Produtos Químicos Farmacêuticos Ltda., LEO Pharma, Sanofi, Daiichi Sankyo Inc., Astellas Pharma Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals.

[City, Date] - DelveInsight's "Venous Thromboembolism Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Venous Thromboembolism, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Venous Thromboembolism Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/venous-thromboembolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Venous Thromboembolism Market Report:
The Venous Thromboembolism market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: Regeneron Pharmaceuticals announced that they are researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery.
In August, 2024: Anthos Therapeutics, Inc. announced a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (Venous Thromboembolism) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated Venous Thromboembolism (Magnolia)
In August, 2024: Anthos Therapeutics, Inc. announced a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (Venous Thromboembolism) recurrence and bleeding in patients with cancer associated Venous Thromboembolism (ASTER)
In June, 2024: Regeneron Pharmaceuticals announced that the primary objective of their study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (Venous Thromboembolism) after unilateral total knee arthroplasty (TKA), compared to enoxaparin.
Venous Thromboembolism affects more than 750,000 individuals each year across the European Union and is responsible for more than 370,000 Venous Thromboembolism-related deaths every year. Long-term complications of Venous Thromboembolism include post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension.
In 2023, the total prevalent cases of Venous Thromboembolism were the highest in the US, which are estimated to increase by 2034.
The US accounted for nearly 50% of total treated cases in 2023, which is expected to increase by 2034.
Key Venous Thromboembolism Companies are as follows: Pfizer, Bristol-Myers Squibb, Bayer, Janssen LLC, Johnson & Johnson Pharma, Cristália Produtos Químicos Farmacêuticos Ltda., LEO Pharma, Sanofi, Daiichi Sankyo Inc., Astellas Pharma Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals.
Key Venous Thromboembolism Therapies are as follow: XARELTO, LIXIANA, Abelacimab, BAY3018250, Sodium enoxaparin, REGN7508, Enoxaparin, YM150, REGN9933, Enoxaparin, Apixiban, DU-176b (edoxaban), BIBR 1048, Semuloparin Sodium, Warfarin
Launching multiple stage Venous Thromboembolism pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Venous Thromboembolism market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/venous-thromboembolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Venous Thromboembolism Overview:
Venous Thromboembolism (Venous Thromboembolism) refers to thromboembolic events within veins, with Deep Vein Thrombosis (DVT) occurring in leg veins and Pulmonary Embolism (PE) in lung arteries.DVT involves blood clot formation in deeper leg veins, often post-major surgeries like knee or hip replacements. PE results from a clot blocking lung arteries, commonly originating in deep leg veins but can also form in arm or pelvic veins.

Venous Thromboembolism Epidemiology Segmentation:
The Venous Thromboembolism market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

Total Incident Cases of Venous Thromboembolism in the US
Total Diagnosed Cases of Venous Thromboembolism in the US
Type-specific Cases of Venous Thromboembolism in the US
Occurrence-specific Cases of Venous Thromboembolism in the US
Total Age-specific Cases of Venous Thromboembolism in the US
Total Prophylactic/Preventive Setting Cases of Venous Thromboembolism in the US
Total Treated Cases of Venous Thromboembolism in Treatment setting in the US
Total Potential (Mortality and Recurrent adjusted) Cases of Venous Thromboembolism in Treatment setting in the US

For more information about Venous Thromboembolism companies working in the treatment market, visit https://www.delveinsight.com/sample-request/venous-thromboembolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Venous Thromboembolism Market Insights
The goal of the therapy for Venous Thromboembolism is to prevent the extension of thrombus, PE and to relieve symptoms in the short term while preventing recurrent events in the long term. It has been suggested recently that Venous Thromboembolism treatment can be divided into two phases: an initial active treatment phase of 3 months and a subsequent secondary prevention phase.

Venous Thromboembolism Treatment Market Insights
Anticoagulants are the primary treatment option for Venous Thromboembolism (Venous Thromboembolism). These medications prevent blood clots from growing larger and aid in the body's gradual reabsorption of existing clots, while also reducing the risk of new clots forming. Warfarin, a Vitamin K antagonist, interferes with the synthesis of clotting factors and is commonly used for both prophylaxis and treatment of Venous Thromboembolism.

Venous Thromboembolism Drugs Uptake
FRAGMIN (dalteparin sodium) is a low molecular weight heparin (LMWH) which was initially approved by the FDA in 1994 for adults and is a type of heparin, which works as an anticoagulant.
PRADAXA (dabigatran etexilate) is a direct thrombin inhibitor which belongs to a drug class called direct-acting oral anticoagulants. PRADAXA oral capsule is available in a generic version but oral pellets are only available in a brandname version
ELIQUIS (apixaban) is a factor Xa inhibitor anticoagulant indicated for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/venous-thromboembolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Venous Thromboembolism Therapies and Key Companies:
LIXIANA (edoxaban): Daiichi Sankyo
XARELTO (rivaroxaban): Janssen Pharmaceuticals/ Bayer
Abelacimab: Anthos Therapeutics
BAY3018250: Bayer
Sodium enoxaparin: Cristália Produtos Químicos Farmacêuticos Ltda.
REGN7508, Enoxaparin: Regeneron Pharmaceuticals
YM150: Astellas Pharma Inc
REGN9933, Enoxaparin, Apixiban: Regeneron Pharmaceuticals
DU-176b (edoxaban): Daiichi Sankyo Co., Ltd.
BIBR 1048: Boehringer Ingelheim
Semuloparin Sodium: Sanofi
Warfarin: LEO Pharma

Venous Thromboembolism Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Venous Thromboembolism.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/venous-thromboembolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Venous Thromboembolism Market Drivers:
Venous Thromboembolism is the third most common cause of vascular mortality worldwide after coronary artery disease and stroke.
Forecasted rise in Venous Thromboembolism cases due to major risk factors like hospitalization, joint replacement, and cancer offers opportunities for drug development, driving market growth.

Venous Thromboembolism Market Barriers:
Anticoagulants cause drug-related adverse events such as life threatening bleeding and impose patient burden from the need for injections, frequent laboratory monitoring, and lifestyle or dietary modifications
Despite the availability of international evidence-based best practice guidelines for Venous Thromboembolism prevention, a significant proportion of patients at risk of Venous Thromboembolism do not receive care as recommended in current guidelines.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/venous-thromboembolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Venous Thromboembolism Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Venous Thromboembolism Companies: Pfizer, Bristol-Myers Squibb, Bayer, Janssen LLC, Johnson & Johnson Pharma, Cristália Produtos Químicos Farmacêuticos Ltda., LEO Pharma, Sanofi, Daiichi Sankyo Inc., Astellas Pharma Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals.
Key Venous Thromboembolism Therapies: XARELTO, LIXIANA, Abelacimab, BAY3018250, Sodium enoxaparin, REGN7508, Enoxaparin, YM150, REGN9933, Enoxaparin, Apixiban, DU-176b (edoxaban), BIBR 1048, Semuloparin Sodium, Warfarin
Venous Thromboembolism Therapeutic Assessment: Current marketed and emerging therapies
Venous Thromboembolism Market Dynamics: Venous Thromboembolism Market drivers and Venous Thromboembolism barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Venous Thromboembolism Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Venous Thromboembolism market outlook, drug uptake, treatment scenario, and epidemiology trends, Venous Thromboembolism Market Forecast @ https://www.delveinsight.com/sample-request/venous-thromboembolism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Venous Thromboembolism (Venous Thromboembolism) Market Overview at a Glance
4. Executive Summary of Venous Thromboembolism (Venous Thromboembolism)
5. Key events
6. Disease Background and Overview
7. Diagnosis of Venous Thromboembolism
8. Current Treatment Practices of Venous Thromboembolism
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Venous Thromboembolism: 7 Major Market Analysis
14. Market Access and Reimbursement
15. KOL views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.